Dietary Reference Intakes based on chronic disease endpoints: outcomes from a case study workshop for omega 3's EPA and DHA.

School of Nursing, Faculty of Health Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada. Bureau of Nutritional Sciences, Health Canada, Ottawa, ON K1A 0K9, Canada. Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS 66160, USA. Department of Kinesiology, Faculty of Health Sciences, University of Waterloo, Waterloo, ON N2L 3G1, Canada. Faculté de Médecine et des Sciences de la Santé, Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada. Centre de Recherche sur le Vieillissement, Centre Intégré Universitaire de Santé et Services Sociaux de l'Estrie-Centre Hospitalier Université de Sherbrooke, Sherbrooke, Quebec, Canada. Faculty of Agricultural, Life and Environmental Sciences, Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AB T6G 2H5, Canada. Food and Nutrition Board, Institute of Medicine, and USDA/ARS Beltsville (retired), Johnson City, TN 37615, USA. Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada. Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada. Canadian Nutrition Society, 867 La Chapelle Street, Ottawa, ON K1C 6A8, Canada. Department of Nutritional Sciences, University of Toronto, Toronto, ON M5S 1A8, Canada. Department of Human Health & Nutritional Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.

Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2021;(5):530-539
Full text from:

Abstract

Given the focus on developing Dietary Reference Intakes (DRIs) based on chronic disease risk reduction and recent research for omega-3 long chain PUFA since the last DRI review, the Canadian Nutrition Society convened a panel of stakeholders for a 1-day workshop in late 2019. Attendees discussed the new NASEM guidelines for establishing DRI values based on chronic disease risk endpoints and the strength of current evidence for EPA and DHA as it relates to the new guidelines. Novelty: Summarizes evidence and expert opinions regarding the potential for reviewing DRI values for EPA and DHA and cardiovascular disease risk and early development.

Methodological quality

Metadata